An impaired endothelial function has been recognized in the early stage of atherosclerosis,
and is a major factor affecting the future development of cardiovascular events. Type 2 …

Context: Antidiabetic therapies based on potentiation of incretin action are now widely used;
however, understanding of their long-term safety remains incomplete. Evidence Acquisition …

The hormone glucagon‐like peptide‐1 (GLP‐1) is released from the gut in response to food
intake. It acts as a satiety signal, leading to reduced food intake, and also as a regulator of …

Purpose The aim of this study is to examine the cardioprotective properties of Glucagon-like
peptide-1 receptor agonist, a class of antihyperglycemic therapy, via meta-analysis of four …

Type 2 diabetes mellitus (T2DM) is a metabolic condition with an elevated impact on
cardiovascular (CV) risk. The innovative therapeutic approaches for T2DM-incretin-based …

The incretins are gut hormones secreted in response to nutrient/carbohydrate ingestion and
act on the pancreatic beta cell to amplify glucose-stimulated insulin secretion. Incretin …

Background Glucose homeostasis is the result of a complex interaction of a spectrum of
hormones, including insulin, glucagon, amylin, and the incretins. Incretins are released by …

The prevalence of obesity continues to grow rapidly worldwide, posing many public health
challenges of the 21st century. Obese subjects are at major risk for serious diet-related …

The incretin hormones glucagon‐like‐peptide‐1 (GLP‐1) and glucose‐dependent
insulinotropic polypeptide (GIP) are released from the intestine following oral ingestion of …

Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)
are gut hormones that are secreted from enteroendocrine L cells and K cells in response to …